• ConcertAI’s TeraRecon launches a complete product portfolio on the cloud, offering new deployment options and broader accessibility of clinical tools for the highest enterprise value
• The new cloud-based SaaS model directly integrates AI-driven insights into clinical workflows, streamlining radiology operations and enhancing patient care
• TeraRecon also announces FDA 510(k) clearance of its AI-based auto-contouring algorithm for short-axis cardiac MR series, further streamlining workflows and driving consistency for assessing cardiac function
• Visit TeraRecon at RSNA 2024 (North Hall Booth #8134) to experience the new Intuition 4.10 release with over 200 enhancements, including cardiac CT and MR workflows and cloud SaaS capabilities

ConcertAI, the leader in predictive and generative AI SaaS and DaaS solutions for healthcare and life sciences, today announced a Software-as-a-Service (SaaS) cloud version of TeraRecon’s AI-enabled portfolio of advanced visualization (AV) and generative AI modules for clinical workflows. This is a milestone in making the best-in-class solution more accessible to healthcare providers, and brings together Intuition Advanced Visualization, Eureka Clinical AI, and CARAai™ in one cloud platform. This addition of the SaaS platform allows healthcare organizations to utilize the latest TeraRecon solutions in different configurations at the enterprise and network levels and assures consistency in AI enabled-workflows everywhere.

The full suite of TeraRecon’s solutions is now available via the cloud, complementing or eliminating the need for on-premises infrastructure while providing seamless access to AI-enabled AV capabilities through a subscription-based service. As part of their subscription, customers gain access to a continuously expanding set of AI-enabled AV applications and generative AI-enabled workflows. This shift aligns with the growing adoption of cloud technology in healthcare, with more than 65% of healthcare organizations worldwide already embracing cloud solutions for core clinical applications.

“ConcertAI is focused on delivering leading-in-class AI SaaS solutions for healthcare’s most time-critical and acute decisions,” said Jeff Elton, PhD, CEO of ConcertAI. “With the broadest multi-modal Data-as-a-Service and leading CARAai™ AI SaaS solutions, we are supporting thousands of clinicians in their diagnosis and treatment decisions for tens of thousands of patients every day. With this combination of cloud and AI SaaS, TeraRecon solutions can assure the productivity of radiological teams globally, timely and accurate diagnoses, and cross-discipline collaboration and care coordination.”

Key advantages of the TeraRecon SaaS advances include:

• Immediate access to the latest AI-enabled clinical tools
• Flexible deployment and scalable infrastructure for various IT environments for healthcare providers and partners
• Automatic software updates and security patches without IT intervention ensures enhanced compliance, including HIPAA, GDPR and SOC2
• Predictable subscription-based pricing model that lowers total cost of ownership and future proofs against future integrations

ConcertAI continues to expand its TeraRecon portfolio of meaningful innovations with the addition of cloud SaaS capabilities, complementing recent advancements such as the Intuition 4.10 advanced visualization software, the FDA 510(k)-cleared AI-driven auto-contouring algorithm for cardiac MR and over 200 feature enhancements informed by physician feedback.

“Our launch of a cloud-based SaaS model represents a turning point in delivering applications to clinicians,” said Sinan Batman, PhD, CTO of TeraRecon. “By making our AI-enabled clinical solutions available through flexible cloud subscription, we’re ensuring healthcare providers and partners have immediate access to the latest clinical solutions where they’re needed most, with standardized workflows for highest productivity, and offered at the lowest total cost of operations. Our latest innovations including new generative AI modules have been well received by our partners. It's exciting to showcase our innovations.”

RSNA 2024 attendees can experience TeraRecon’s latest innovations, including the new Intuition platform with over 200 feature enhancements, at North Hall Booth #8134 (McCormick Place, Chicago). To schedule a demonstration or meeting, visit TeraRecon’s website.

In addition to the booth exhibit, TeraRecon offers engaging customer events designed to foster peer-to-peer learning and hands-on experience with the latest advancements.

About ConcertAI

ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241202029158/en/